Senescence-related signatures

1. Senescence-related signatures predict survival in silico.

   “The SRS model stratified patients into high- and low-risk groups with distinct survival outcomes”

   In silicocervical cancer

   A senescence-based machine learning model prognosticates and personalizes therapy in cervical cancer

   Translational cancer research·13 May 2026

1. Senescence-related signatures predict response to immune checkpoint inhibitors in humans.

   “Patients exhibiting low expression levels of the senescence-related signature responded more favorably to immune checkpoint inhibitors in various solid tumors, including LUAD.”

   Humanslow signature expression in solid tumors, including lung adenocarcinoma

   Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy

   Heliyon·8 Aug 2024

1. Senescence-related signatures are associated with tumor-infiltrating neutrophils in humans.

   “demonstrated a negative association with antitumor immunity and tumor-infiltrating neutrophils.”

   Humanslung adenocarcinomatumor

   Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy

   Heliyon·8 Aug 2024

More on Tumor-infiltrating neutrophils

1. Senescence-related signatures are associated with antitumor immunity in humans.

   “demonstrated a negative association with antitumor immunity and tumor-infiltrating neutrophils.”

   Humanslung adenocarcinoma

   Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy

   Heliyon·8 Aug 2024

1. Senescence-related signatures predict survival outcomes in humans.

   “was identified to have predictive significance across multiple LUAD cohorts”

   Humanslung adenocarcinoma

   Deciphering the predictive value of senescence-related signature in lung adenocarcinoma: Implications for antitumor immunity and immunotherapy efficacy

   Heliyon·8 Aug 2024